How Ozempic Almost Never Happened

By now, if you haven’t used Ozempic, you’ve definitely heard of it. 💉

In fact, around one in eight US adults is currently taking a GLP-1 drug. It's on every talk show, in every group chat, and has become a cultural phenomenon that's reshaping entire industries from healthcare to fashion to food.

As per latest estimates, it’s a $190 billion market and climbing. 📈

So, it may surprise you that the formula sat pretty much untouched for over 30 years because one very powerful company looked at it, shrugged, and walked away.

And you’ll never believe this, but that company was Pfizer. 😬

In the late 1980s, a startup developed a GLP-1 compound — the same class of drug that would eventually become Ozempic and Wegovy. Pfizer actually sponsored the human trials and the results were genuinely promising. The drug effectively lowered blood glucose, slowed digestion, and reduced hunger.

Scientifically, it worked.

And then Pfizer's senior leadership made a call that will go down in business history as one of the most expensive misjudgments ever made. They concluded (with total confidence, btw) that there would never be another injectable therapy for diabetes other than insulin. 😒

So in 1991, they pulled the plug entirely, and the startup folded.

The license reverted to the Boston hospital where the original research had been done. Novo Nordisk picked it up in 1992 and spent the next few decades developing what eventually became semaglutide — the pharmaceutical phenomenon now sold as Ozempic and Wegovy and generating billions today. 💸

Where the story gets interesting from a business perspective though is that Pfizer didn't lose this because the idea was bad. They lost it because they couldn't see past one application to imagine what else it could become.

Ozempic isn't a story of a great invention but rather how said great invention nearly went nowhere — and the distinction matters enormously.

The idea wasn’t ground breaking — it had existed for decades. What unveiled its value wasn't the science but someone finally recognizing what the market actually wanted, and working toward building that. 🏗️

This pattern shows up constantly throughout business history, by the way. Henry Ford didn't invent the car — he invented the “affordable” car, and realised what ordinary people actually wanted from it before anyone else did.

Or take Nikola Tesla's patents, which were bought by George Westinghouse, who commercialised them while Tesla died in poverty. Likewise, Elias Howe invented the sewing machine but Isaac Singer is the name everyone remembers, because Singer understood the market. And… this one may also surprise you, Antonio Meucci invented the telephone but Alexander Graham Bell had the resources and instincts to make it mean something. 📞

The invention is rarely the valuable part. The execution and marketing, AKA turning a discovery into something people will actually pay for, let alone at scale, is where the real value gets created.

We're taught that being first matters most. Get there before everyone else, plant the flag, register the trademark and own the market. Sure, sometimes that's true.

But the Ozempic story is a case study in what's called second-mover advantage — and it's far more common than people realize.

Novo Nordisk didn't invent GLP-1s. They got hold of a license that a bigger company had thrown away, and had the vision to see what Pfizer couldn’t. 💡

Why this works is that second movers don't just avoid the first mover's mistakes. They go into it with a clearer picture of what the market actually wants — because by the time they show up, there's usually more information available.

You can think of it as the first mover essentially doing R&D for everyone who came after. 🎯

Which means that if you've ever looked at your industry and thought "someone already tried this and it didn't work" — that's not necessarily a sign to quit. This might be the most valuable (and possibly free) piece of market research you have.

For all those businesses that feel like “there’s always someone doing this better,” here’s a small but significant note of reassurance.

The GLP-1 compound wasn't wrong and it definitely wasn't a bad idea. It was simply ahead of its moment, and in the wrong hands at the wrong time. 😒

The world wasn't ready, or the right person hadn't found it yet, or the market that would eventually go crazy for it didn't exist in the form it needed to.

That happens to ideas all the time and it happens to businesses more often than you think.

Perhaps even you’re sitting on something that hasn't clicked yet — a product that launched too early, a concept the market hasn't caught up to, or an idea that got dismissed by someone who simply couldn't see the application.

The right execution, at the right moment, by someone with the right vision? That's what turns a junk drawer full of promising data into a multi-billion dollar market. 🚀